Photokinetic Drug Delivery

Near infrared (NIR) Induced Permeation Enhancement of Bevacizumab, Ranibizumab and Aflibercept through Human Sclera

Steven A. Giannos, Edward R. Kraft, Zhen Yang Zhao, Kevin Merkley, Jiyang Cai

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose: Permeation studies, with near infrared (NIR) light and anti-aggregation antibody formulation, were used to investigate the in vitro permeation of bevacizumab, ranibizumab and aflibercept through human sclera. Methods: A vertical, spherical Franz cell diffusion apparatus was used for this scleral tissue permeation model. A photokinetic ocular drug delivery (PODD) testing device accommodated the placement of NIR LEDs above the donor chambers. An adjustable LED driver/square wave generator provided electrical energy with a variable pulse rate and pulse width modulation (duty cycle). Results: Exposure to non-thermal NIR light had no effect on mAbs with regard to monomer concentration or antibody binding potential, as determined by SE-HPLC and ELISA. The optimal LED wavelength was found to be 950 nm. Duty cycle power of 5% vs 20% showed no difference in permeation. When compared to controls, the combination of non-aggregating antibody formulation and NIR illumination provided an average transscleral drug flux enhancement factor of 3X. Conclusion: Narrow wavelength incoherent (non-laser) light from an NIR LED source is not harmful to mAbs and can be used to enhance drug permeation through scleral tissue. The topical formulation, combined with pulsed NIR light irradiation, significantly improved scleral permeation of three anti-VEGF antibody drugs.

Original languageEnglish (US)
Article number110
JournalPharmaceutical Research
Volume35
Issue number6
DOIs
StatePublished - Jun 1 2018

Fingerprint

Sclera
Drug delivery
Permeation
Infrared radiation
Light
Light emitting diodes
Pharmaceutical Preparations
Anti-Idiotypic Antibodies
Antibodies
Square wave generators
Lighting
Tissue
Vascular Endothelial Growth Factor A
Wavelength
Heart Rate
Enzyme-Linked Immunosorbent Assay
High Pressure Liquid Chromatography
Equipment and Supplies
Pulse width modulation
Light sources

Keywords

  • aflibercept
  • bevacizumab
  • permeation
  • photokinetic
  • ranibizumab
  • sclera

ASJC Scopus subject areas

  • Biotechnology
  • Molecular Medicine
  • Pharmacology
  • Pharmaceutical Science
  • Organic Chemistry
  • Pharmacology (medical)

Cite this

Photokinetic Drug Delivery : Near infrared (NIR) Induced Permeation Enhancement of Bevacizumab, Ranibizumab and Aflibercept through Human Sclera. / Giannos, Steven A.; Kraft, Edward R.; Zhao, Zhen Yang; Merkley, Kevin; Cai, Jiyang.

In: Pharmaceutical Research, Vol. 35, No. 6, 110, 01.06.2018.

Research output: Contribution to journalArticle

@article{61741c66bee04a22932bb26de291258c,
title = "Photokinetic Drug Delivery: Near infrared (NIR) Induced Permeation Enhancement of Bevacizumab, Ranibizumab and Aflibercept through Human Sclera",
abstract = "Purpose: Permeation studies, with near infrared (NIR) light and anti-aggregation antibody formulation, were used to investigate the in vitro permeation of bevacizumab, ranibizumab and aflibercept through human sclera. Methods: A vertical, spherical Franz cell diffusion apparatus was used for this scleral tissue permeation model. A photokinetic ocular drug delivery (PODD) testing device accommodated the placement of NIR LEDs above the donor chambers. An adjustable LED driver/square wave generator provided electrical energy with a variable pulse rate and pulse width modulation (duty cycle). Results: Exposure to non-thermal NIR light had no effect on mAbs with regard to monomer concentration or antibody binding potential, as determined by SE-HPLC and ELISA. The optimal LED wavelength was found to be 950 nm. Duty cycle power of 5{\%} vs 20{\%} showed no difference in permeation. When compared to controls, the combination of non-aggregating antibody formulation and NIR illumination provided an average transscleral drug flux enhancement factor of 3X. Conclusion: Narrow wavelength incoherent (non-laser) light from an NIR LED source is not harmful to mAbs and can be used to enhance drug permeation through scleral tissue. The topical formulation, combined with pulsed NIR light irradiation, significantly improved scleral permeation of three anti-VEGF antibody drugs.",
keywords = "aflibercept, bevacizumab, permeation, photokinetic, ranibizumab, sclera",
author = "Giannos, {Steven A.} and Kraft, {Edward R.} and Zhao, {Zhen Yang} and Kevin Merkley and Jiyang Cai",
year = "2018",
month = "6",
day = "1",
doi = "10.1007/s11095-018-2392-7",
language = "English (US)",
volume = "35",
journal = "Pharmaceutical Research",
issn = "0724-8741",
publisher = "Springer New York",
number = "6",

}

TY - JOUR

T1 - Photokinetic Drug Delivery

T2 - Near infrared (NIR) Induced Permeation Enhancement of Bevacizumab, Ranibizumab and Aflibercept through Human Sclera

AU - Giannos, Steven A.

AU - Kraft, Edward R.

AU - Zhao, Zhen Yang

AU - Merkley, Kevin

AU - Cai, Jiyang

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Purpose: Permeation studies, with near infrared (NIR) light and anti-aggregation antibody formulation, were used to investigate the in vitro permeation of bevacizumab, ranibizumab and aflibercept through human sclera. Methods: A vertical, spherical Franz cell diffusion apparatus was used for this scleral tissue permeation model. A photokinetic ocular drug delivery (PODD) testing device accommodated the placement of NIR LEDs above the donor chambers. An adjustable LED driver/square wave generator provided electrical energy with a variable pulse rate and pulse width modulation (duty cycle). Results: Exposure to non-thermal NIR light had no effect on mAbs with regard to monomer concentration or antibody binding potential, as determined by SE-HPLC and ELISA. The optimal LED wavelength was found to be 950 nm. Duty cycle power of 5% vs 20% showed no difference in permeation. When compared to controls, the combination of non-aggregating antibody formulation and NIR illumination provided an average transscleral drug flux enhancement factor of 3X. Conclusion: Narrow wavelength incoherent (non-laser) light from an NIR LED source is not harmful to mAbs and can be used to enhance drug permeation through scleral tissue. The topical formulation, combined with pulsed NIR light irradiation, significantly improved scleral permeation of three anti-VEGF antibody drugs.

AB - Purpose: Permeation studies, with near infrared (NIR) light and anti-aggregation antibody formulation, were used to investigate the in vitro permeation of bevacizumab, ranibizumab and aflibercept through human sclera. Methods: A vertical, spherical Franz cell diffusion apparatus was used for this scleral tissue permeation model. A photokinetic ocular drug delivery (PODD) testing device accommodated the placement of NIR LEDs above the donor chambers. An adjustable LED driver/square wave generator provided electrical energy with a variable pulse rate and pulse width modulation (duty cycle). Results: Exposure to non-thermal NIR light had no effect on mAbs with regard to monomer concentration or antibody binding potential, as determined by SE-HPLC and ELISA. The optimal LED wavelength was found to be 950 nm. Duty cycle power of 5% vs 20% showed no difference in permeation. When compared to controls, the combination of non-aggregating antibody formulation and NIR illumination provided an average transscleral drug flux enhancement factor of 3X. Conclusion: Narrow wavelength incoherent (non-laser) light from an NIR LED source is not harmful to mAbs and can be used to enhance drug permeation through scleral tissue. The topical formulation, combined with pulsed NIR light irradiation, significantly improved scleral permeation of three anti-VEGF antibody drugs.

KW - aflibercept

KW - bevacizumab

KW - permeation

KW - photokinetic

KW - ranibizumab

KW - sclera

UR - http://www.scopus.com/inward/record.url?scp=85044762105&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044762105&partnerID=8YFLogxK

U2 - 10.1007/s11095-018-2392-7

DO - 10.1007/s11095-018-2392-7

M3 - Article

VL - 35

JO - Pharmaceutical Research

JF - Pharmaceutical Research

SN - 0724-8741

IS - 6

M1 - 110

ER -